Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Coherus Oncology (CHRS) Return on Invested Capital (2020)

Historic Return on Invested Capital for Coherus Oncology (CHRS) over the last 4 years, with Q4 2023 value amounting to 1.27%.

  • Coherus Oncology's Return on Invested Capital changed N/A to 1.27% in Q4 2023 from the same period last year, while for Dec 2023 it was 1.27%, marking a year-over-year change of. This contributed to the annual value of 1.24% for FY2023, which is N/A changed from last year.
  • Per Coherus Oncology's latest filing, its Return on Invested Capital stood at 1.27% for Q4 2023.
  • Coherus Oncology's 5-year Return on Invested Capital high stood at 1.27% for Q4 2023, and its period low was 0.56% during Q3 2021.
  • Over the past 4 years, Coherus Oncology's median Return on Invested Capital value was 0.29% (recorded in 2019), while the average stood at 0.4%.
  • Its Return on Invested Capital has fluctuated over the past 5 years, first soared by 9500bps in 2020, then plummeted by -16200bps in 2021.
  • Coherus Oncology's Return on Invested Capital (Quarter) stood at 0.18% in 2019, then soared by 123bps to 0.4% in 2020, then crashed by -241bps to 0.56% in 2021, then soared by 327bps to 1.27% in 2023.
  • Its Return on Invested Capital was 1.27% in Q4 2023, compared to 1.22% in Q3 2023 and 0.56% in Q3 2021.